R. Erik  Holmlin net worth and biography

R. Holmlin Biography and Net Worth

Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and health care industries.

Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.

Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

How do I contact R. Erik Holmlin?

The corporate mailing address for Dr. Holmlin and other Bionano Genomics executives is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. Bionano Genomics can also be reached via phone at (858) 888-7600 and via email at [email protected]. Learn More on R. Erik Holmlin's contact information.

Has R. Erik Holmlin been buying or selling shares of Bionano Genomics?

R. Erik Holmlin has not been actively trading shares of Bionano Genomics during the last ninety days. Learn More on R. Erik Holmlin's trading history.

R. Erik Holmlin Insider Trading History at Bionano Genomics

See Full Table

R. Erik Holmlin Buying and Selling Activity at Bionano Genomics

This chart shows R. Erik Holmlin's buying and selling at Bionano Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bionano Genomics Company Overview

Bionano Genomics logo
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.20
Low: $0.20
High: $0.20

50 Day Range

MA: $0.27
Low: $0.20
High: $0.35

2 Week Range

Now: $0.20
Low: $0.20
High: $2.27

Volume

2,426,787 shs

Average Volume

1,906,710 shs

Market Capitalization

$19.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28